ClinicalTrials.gg
RecruitingNCT05890781IMMUNEORGANOIDUpdated Feb 9, 2026

Engineering Immune Organoids to Study Pediatric Cancer

An interventional study of Skin biopsy and Fresh tumor sample in Brain Tumor, Kidney Tumor and Neuroblastoma, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 2 sites in France. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
Up to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Brain Neoplasms with a site in France — 38 open to participants now, 52 under way, 6 of them phase 3. Brain Neoplasms · France.

Planned enrollment
49th of 132
108 · median 70
Started
2023
with 11 others
No phase
45 of 172
18 open now
Primary completion
2028-05
later than 28 of 51 live
Registered
143rd of 172
by date
Lead sponsor
5 of 172
Gustave Roussy, Cancer Campus, Grand Paris

Among the 172 studies in Brain Neoplasms with a site in France, this one is the 49th largest by planned enrollment of the 132 interventional ones that give a count, is one of 12 that started in 2023, is one of 45 with no phase, reaches primary completion later than 28 of the 51 other live ones, and was the 143rd registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

38 of the 172 studies in Brain Neoplasms with a site in France are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: Up to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Brain Neoplasms with a site in France, or all of them as a file.
02

Study summary

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

03

Conditions studied

  • Brain Tumor
  • Kidney Tumor
  • Neuroblastoma
  • Sarcoma
04

Who can participate

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
  • Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
  • Brain tumors
  • Renal tumors
  • Neuroblastoma
  • Sarcomas
  • Adult patient or parents or guardians should understand, sign and date the appropriate written from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
  • Affiliated to a social security system or beneficiary of the same.

Exclusion criteria

Exclusion Criteria:

  • Any histology not mentioned in the inclusion criteria
  • Adult patient or parents/guardians incapable/incapable of giving its/their consent
  • Patients deprived of their liberty by a judicial or administrative decision
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Other
    Immune organoids from pediatric patient tissues using iPSC

    To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

    Procedure: Skin biopsy · Procedure: Fresh tumor sample · Biological: Blood sample · Procedure: Healthy tissue from the tumor · Procedure: Spinal cerebrospinal fluid (SCF)

Interventions

  • ProcedureSkin biopsy

    Skin biopsy

  • ProcedureFresh tumor sample

    Fresh tumor sample

  • BiologicalBlood sample

    Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached

  • ProcedureHealthy tissue from the tumor

    Healthy tissue from the tumor site whenever possible

  • ProcedureSpinal cerebrospinal fluid (SCF)

    Spinal cerebrospinal fluid (SCF) whenever possible

06

What researchers measure

Primary outcomes

  1. Proportion of viable and exploitable immune organoids with engrafted tumor cells

    Time frame: until 5 years after enrolment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2028, 60 months after the start.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 60 months is close to that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2023
First posted
Jun 6, 2023
StartActual
May 12, 2023
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05890781
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
May 12, 2023
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Feb 9, 2026

Study contacts

Claudia PASQUALINI, MD
Contact
claudia.pasqualini@gustaveroussy.fr
+33 (0)1 42 11 55 31
Jérémy MIONE, MS
Contact
jeremy.mione@gustaveroussy.fr
+33 (0)1 42 11 42 11 ext. 38 61

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion